Kerwin, Edward
Ferguson, Gary T.
Sanjar, Shahin
Goodin, Thomas
Yadao, Anthony
Fogel, Robert
Maitra, Samopriyo
Sen, Biswajit
Ayers, Tim
Banerji, Donald
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies
https://doi.org/10.1007/s00408-017-0055-9
Documents that mention this clinical trial
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies
https://doi.org/10.1007/s00408-017-0055-9
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 31 July 2017
Accepted: 11 September 2017
First Online: 9 October 2017
Compliance with Ethical Standards
:
: EK and GTF were principal investigators on the studies. SS and TG are employees of Sunovion Pharmaceuticals Inc. AY, RF, SM, BS, TA, and DB are employees of Novartis Pharmaceuticals Corporation or Novartis Healthcare Pvt. Ltd.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (ClinicalTrials.gov NCT02487446 and NCT02487498).
: Informed consent was obtained from all individual participants included in the study.